A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
NRG Oncology
Novartis
National Cancer Institute (NCI)
AstraZeneca
Eli Lilly and Company
Stemline Therapeutics, Inc.
Eli Lilly and Company
Centre Oscar Lambret
Olema Pharmaceuticals, Inc.
Sun Yat-sen University
University of Virginia
Alliance Foundation Trials, LLC.
SWOG Cancer Research Network
ETOP IBCSG Partners Foundation
ETOP IBCSG Partners Foundation
Genentech, Inc.
Shandong Suncadia Medicine Co., Ltd.
Fudan University
Tolmar Inc.
Tolmar Inc.
National Cancer Institute (NCI)
UNICANCER
Japanese Foundation for Cancer Research
Jiangsu Simcere Pharmaceutical Co., Ltd.
Stemline Therapeutics, Inc.
Azienda Ospedaliero-Universitaria Careggi
European Organisation for Research and Treatment of Cancer - EORTC
Eli Lilly and Company
AstraZeneca
Institute of Cancer Research, United Kingdom
Alliance for Clinical Trials in Oncology
Region Örebro County
Spanish Breast Cancer Research Group
University of Ulm
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Veru Inc.
Fudan University
Veru Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Chipscreen Biosciences, Ltd.
Novartis
Gruppo Italiano Mammella (GIM)
Dharmais National Cancer Center Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Novartis
Novartis
ETOP IBCSG Partners Foundation
ETOP IBCSG Partners Foundation